# Clinical Core-Core 6

> **NIH NIH P30** · UNIVERSITY OF IOWA · 2022 · $112,321

## Abstract

Abstract/Summary (Clinical Core–Core 6)
The Clinical Core (Core 6) facilitates translational research in CF human subjects and human samples. This
P30 Core facility was established at the time of the last renewal due to the increasing need for organized
biobanking of CF and non-CF control specimens and the increasing involvement of Center Members in clinical
studies seeking to ask basic scientific questions in humans and compare these findings to the CF mouse,
ferret and pig models. Major objectives of the core include assistance in recruiting and identifying patients
suitable for various investigator-driven CF clinical trials and studies. This Core functions under the umbrella of
the Institute for Clinical and Translational Science (ICTS) and will benefit from its resources and support for
translational clinical research.
The main goals of the Core are:
 1. To sustain an umbrella biobank to archive biosamples collected during routine clinical visits and
 research-related visits, and to obtain consent from current and future CF patients for this biobank.
 2. To acquire normal and CF specimens including DNA, bronchoalveolar lavage fluid (BALF), whole
 blood, plasma, feces, urine, and bacterial isolates.
 3. To maintain databases of historical clinical samples and prospectively collected samples, including
 molecular typing of bacterial and other isolates when available.
 4. To support a standardized process through which investigators can obtain de-identified or identified
 clinical information about archived clinical samples or prospectively obtained samples from routine
 clinical bloodwork (e.g. samples from oral glucose tolerance testing, or routine liver function monitoring)
 5. To assist basic and translational researchers in obtaining specific biological samples that are not
 routinely banked (e.g. surgical discarded specimens such as the gallbladder following
cholecystectomy).
 6. To facilitate patient recruitment and enrollment in clinical trials and studies, particularly early phase
 trials of novel therapies and mechanistic or pathophysiology studies.
 7. To assist investigators in conducting clinical trials and preparing IRB submissions, and to ensure that
 clinical research is conducted in accordance with the principles of Good Clinical Practice (GCP), and
 appropriate biostatistical analysis.

## Key facts

- **NIH application ID:** 10436231
- **Project number:** 5P30DK054759-23
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** Katie Marie Ulring Larson Ode
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $112,321
- **Award type:** 5
- **Project period:** 1998-09-30 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10436231

## Citation

> US National Institutes of Health, RePORTER application 10436231, Clinical Core-Core 6 (5P30DK054759-23). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10436231. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*